Images in Clinical Medicine
Lipodystrophy Associated with an HIV-Protease Inhibitor
N Engl J Med 1998; 339:1296October 29, 1998
- Article
Figure 1 A 53-year-old man had human immunodeficiency virus (HIV)–related lymphoma, which had been in remission since 1987; a CD4+ lymphocyte count of 510 cells per cubic millimeter; and an HIV RNA load of 5000 copies per milliliter. The addition of the HIV-protease inhibitor indinavir (800 mg three times daily) to his antiretroviral regimen of zidovudine and lamivudine resulted in a decrease in the HIV RNA load to undetectable levels and an increase in the CD4+ count to 918 cells per cubic millimeter. Measurement of cholesterol (298 mg per deciliter [7.7 mmol per liter]; reference range, <193 mg per deciliter [5.0 mmol per liter]), triglycerides (239 mg per deciliter [2.7 mmol per liter]; reference range, <177 mg per deciliter [2.0 mmol per liter]), and C peptide (4.0 μg per liter; reference range, 0.9 to 1.8 μg per liter) while the patient was fasting revealed hypercholesterolemia, hypertriglyceridemia, and insulin resistance. Impaired glucose tolerance was diagnosed on the basis of a glucose-tolerance test (blood glucose, 108 mg per deciliter [6.0 mmol per liter] during fasting and 176 mg per deciliter [9.8 mmol per liter] at two hours). Within three to seven months after the initiation of indinavir, fat wasting of the face (Panel A), arms, buttocks, and legs developed, and the leg and arm veins became prominent. There was concurrent central obesity (Panel B) and enlargement of the cervicodorsal fat pad, referred to as buffalo hump (Panel C). Loss of body fat was confirmed by dual-energy x-ray absorptiometry. Clinically, muscle mass and strength were normal, and there was no abdominal organomegaly, mass, or ascites. The fasting morning plasma cortisol concentration was 11 μg per deciliter (308 nmol per liter; reference range, 7 to 22 μg per deciliter [200 to 600 nmol per liter]). These changes have continued to progress during the 19 months of therapy. The patient expressed concern about continuing indinavir therapy because of his physical appearance (a friend commented that he looked as though he had AIDS) and the potential risk of long-term cardiovascular disease.
Andrew Carr, M.D.
St. Vincent's Hospital, Sydney 2010, AustraliaDavid A. Cooper, D.Sc., M.D.
University of New South Wales, Sydney 2010, Australia- Citing Articles (42)
Citing Articles
1
Carla M. T. Fourie, Johannes M. Rooyen, Annamarie Kruger, Michael H. Olsen, Jesper Eugen-Olsen, Rudolph Schutte, Aletta E. Schutte. (2011) Soluble Urokinase Plasminogen Activator Receptor (suPAR) is Associated with Metabolic Changes in HIV-1-Infected Africans: A Prospective Study. Inflammation
CrossRef2
S. Tsiodras, A. Perelas, C. Wanke, C.S. Mantzoros. (2010) The HIV-1/HAART associated metabolic syndrome – Novel adipokines, molecular associations and therapeutic implications. Journal of Infection 61:2, 101-113
CrossRef3
Carla Maria T. Fourie, Johannes M. Rooyen, Annamarie Kruger, Aletta E. Schutte. (2010) Lipid Abnormalities in a Never-Treated HIV-1 Subtype C-Infected African Population. Lipids 45:1, 73-80
CrossRef4
M. Gerschenson, C. Kim, B. Berzins, B. Taiwo, D. E. Libutti, J. Choi, D. Chen, J. Weinstein, J. Shore, B. da Silva, E. Belsey, G. A. McComsey, R. L. Murphy. (2009) Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen. Journal of Antimicrobial Chemotherapy 63:6, 1244-1250
CrossRef5
Georg MN Behrens. (2008) Treatment options for lipodystrophy in HIV-positive patients. Expert Opinion on Pharmacotherapy 9:1, 39-52
CrossRef6
David Alain Wohl. (2007) Considering metabolic issues when initiating HIV therapy. Current HIV/AIDS Reports 4:3, 119-125
CrossRef7
Todd Hulgan. (2007) Nucleoside and nucleotide analogue reverse transcriptase inhibitor toxicity: how much longer must we wield the sword?. Future HIV Therapy 1:1, 61-72
CrossRef8
2007. Cushing's Syndrome. , 109-118.
CrossRef9
2006. Protease inhibitors. , 2965-2971.
CrossRef10
Katrin Utech, Kaspar Berneis. 2005. Cachexia Associated with AIDS. , 143-164.
CrossRef11
Sheila Collins. (2005) Overview of clinical perspectives and mechanisms of obesity. Birth Defects Research Part A: Clinical and Molecular Teratology 73:7, 470-471
CrossRef12
Elizabeth Burgess, Christine Wanke. (2005) Use of recombinant human growth hormone in HIV-associated lipodystrophy. Current Opinion in Infectious Diseases 18:1, 17-24
CrossRef13
Grinspoon, Steven, Carr, Andrew, . (2005) Cardiovascular Risk and Body-Fat Abnormalities in HIV-Infected Adults. New England Journal of Medicine 352:1, 48-62
Full Text14
A. Rudich, R. Ben-Romano, S. Etzion, N. Bashan. (2005) Cellular mechanisms of insulin resistance, lipodystrophy and atherosclerosis induced by HIV protease inhibitors. Acta Physiologica Scandinavica 183:1, 75-88
CrossRef15
Bruno Fève, Martine Glorian, Khadija El Hadri. (2004) Pathophysiology of the HIV-Associated Lipodystrophy Syndrome. Metabolic Syndrome and Related Disorders 2:4, 274-286
CrossRef16
Frank J. Palella, Jr., Stephen R. Cole, Joan S. Chmiel, Sharon A. Riddler, Barbara Visscher, Adrian Dobs, Carolyn Williams. (2004) Anthropometrics and Examiner‐Reported Body Habitus Abnormalities in the Multicenter AIDS Cohort Study. Clinical Infectious Diseases 38:6, 903-907
CrossRef17
Kai Kappert, Evren Caglayan, Anselm T B??umer, Michael S??dkamp, Gerd F??tkenheuer, Stephan Rosenkranz. (2004) Ritonavir exhibits anti-atherogenic properties on vascular smooth muscle cells. AIDS 18:3, 403-411
CrossRef18
Polyxeni Koutkia, Steven Grinspoon. (2004) HIV–Associated Lipodystrophy: Pathogenesis, Prognosis, Treatment, and Controversies. Annual Review of Medicine 55:1, 303-317
CrossRef19
Hans O. Andersson, Kerstin Fridborg, Seved Lowgren, Mathias Alterman, Anna Muhlman, Magnus Bjorsne, Neeraj Garg, Ingmar Kvarnstrom, Wesley Schaal, Bjorn Classon, Anders Karlen, U. Helena Danielsson, Goran Ahlsen, Ullrika Nillroth, Lotta Vrang, Bo Oberg, Bertil Samuelsson, Anders Hallberg, Torsten Unge. (2003) Optimization of P1-P3 groups in symmetric and asymmetric HIV-1 protease inhibitors. European Journal of Biochemistry 270:8, 1746-1758
CrossRef20
Kenneth A. Lichtenstein, Kathleen M. Delaney, Carl Armon, Douglas J. Ward, Anne C. Moorman, Kathleen C. Wood, Scott D. Holmberg. (2003) Incidence of and Risk Factors for Lipoatrophy (Abnormal Fat Loss) in Ambulatory HIV-1-Infected Patients. JAIDS Journal of Acquired Immune Deficiency Syndromes 32:1, 48-56
CrossRef21
Bridget Maher, Ana Alfirevic, F Javier Vilar, Edmund GL Wilkins, B Kevin Park, Munir Pirmohamed. (2002) TNF-α promoter region gene polymorphisms in HIV-positive patients with lipodystrophy. AIDS 16:15, 2013-2018
CrossRef22
D Worm, O Kirk, O Andersen, J Vinten, J Gerstoft, TL Katzenstein, H Nielsen, C Pedersen. (2002) Clinical lipoatrophy in HIV-1 patients on HAART is not associated with increased abdominal girth, hyperlipidaemia or glucose intolerance. HIV Medicine 3:4, 239-246
CrossRef23
Bruno Spire, Ségolène Duran, Marc Souville, Catherine Leport, François Raffi, Jean-Paul Moatti. (2002) Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach. Social Science & Medicine 54:10, 1481-1496
CrossRef24
William G. Powderly. (2002) Long-term Exposure to Lifelong Therapies. JAIDS Journal of Acquired Immune Deficiency Syndromes 29, S28-S40
CrossRef25
Mar??a Graciela Cers??simo, Beatriz Lasala, Silvia Folgar, Federico Micheli. (2002) Epidural Lipomatosis Secondary to Indinavir in an HIV-Positive Patient. Clinical Neuropharmacology 25:1, 51-54
CrossRef26
Mark A. Chastain, Jennifer Buckley Chastain, William P. Coleman. (2001) HIV Lipodystrophy: Review of the Syndrome and Report of a Case Treated with Liposuction. Dermatologic Surgery 27:5, 497-500
CrossRef27
Stephen M. Arpadi, Patricia A. Cuff, Mary Horlick, Jack Wang, Donald P. Kotler. (2001) Lipodystrophy in HIV-Infected Children Is Associated With High Viral Load and Low CD4+-Lymphocyte Count and CD4+-Lymphocyte Percentage at Baseline and Use of Protease Inhibitors and Stavudine. JAIDS Journal of Acquired Immune Deficiency Syndromes 27:1, 30-34
CrossRef28
Stephen M. Arpadi, Patricia A. Cuff, Mary Horlick, Jack Wang, Donald P. Kotler. (2001) Lipodystrophy in HIV-Infected Children Is Associated With High Viral Load and Low CD4+-Lymphocyte Count and CD4+-Lymphocyte Percentage at Baseline and Use of Protease Inhibitors and Stavudine. Journal of Acquired Immune Deficiency Syndromes 27:1, 30-34
CrossRef29
Michele S. Cauble, Richard Gilroy, Michael F. Sorrell, Mark E. Mailliard, Debra L. Sudan, Joseph C. Anderson, James L. Wisecarver, Sajeev Balakrishnan, Jennifer L. Larsen. (2001) LIPOATROPHIC DIABETES AND END-STAGE LIVER DISEASE SECONDARY TO NONALCOHOLIC STEATOHEPATITIS WITH RECURRENCE AFTER LIVER TRANSPLANTATION. Transplantation 71:7, 892-895
CrossRef30
J. R. Ebright, M. A. Stellini, A. C. Tselis. (2001) Spinal Epidural Lipomatosis in a Human Immunodeficiency Virus-Positive Patient Receiving Steroids and Protease Inhibitor Therapy. Clinical Infectious Diseases 32:5, e90-e91
CrossRef31
Kai Riecke, Thomas G. Schulz, Mehdi Shakibaei, Bernd Krause, Ibrahim Chahoud, Ralf Stahlmann. (2000) Developmental toxicity of the HIV-protease inhibitor indinavir in rats. Teratology 62:5, 291-300
CrossRef32
Neil M. Graham. (2000) Metabolic Disorders Among HIV-Infected Patients Treated With Protease Inhibitors: A Review. JAIDS Journal of Acquired Immune Deficiency Syndromes 25, S4-S11
CrossRef33
Neil M. Graham. (2000) Metabolic Disorders Among HIV-Infected Patients Treated With Protease Inhibitors: A Review. Journal of Acquired Immune Deficiency SyndromesS4-S11
CrossRef34
Daniel A. Carrasco, Melody Vander Straten, Stephen K. Tyring. (2000) A review of antiretroviral drugs. Dermatologic Therapy 13:3, 305-317
CrossRef35
Kayla Alligood, Colleen M. Terriff. (2000) Cardiovascular Complications of HIV. Progress in Cardiovascular Nursing 15:3, 104-109
CrossRef36
P. HAYES, D. MULLER, D. KUCHAR. (2000) Left main coronary artery disease in a 40-year-old man receiving HIV protease inhibitors. Australian and New Zealand Journal of Medicine 30:1, 92-93
CrossRef37
Roula B. Qaqish, Evelyn Fisher, John Rublein, David A. Wohl. (2000) HIV-Associated Lipodystrophy Syndrome. Pharmacotherapy 20:1, 13-22
CrossRef38
Georg M.N. Behrens, Matthias Stoll, Reinhold E. Schmidt. (2000) Lipodystrophy Syndrome in HIV Infection. Drug Safety 23:1, 57-76
CrossRef39
Francis G. Wolfort, Curtis L. Cetrulo, Daniel R. Nevarre. (1999) Suction-Assisted Lipectomy for Lipodystrophy Syndromes Attributed to HIV-Protease Inhibitor Use. Plastic & Reconstructive Surgery 104:6, 1814-1820
CrossRef40
Frances Gotch, Gareth Hardy, Nesrina Imami. (1999) Therapeutic vaccines in HIV. 1 infection. Immunological Reviews 170:1, 173-182
CrossRef41
(1999) Fat Distribution in AIDS. New England Journal of Medicine 340:12, 969-970
Full Text42
&NA;. (1998) Indinavir. Reactions Weekly &NA;:728, 8
CrossRef
- Letters
